CLINICAL TRIALS PROFILE FOR ANIDULAFUNGIN
✉ Email this page to a colleague
All Clinical Trials for Anidulafungin
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00037206 ↗ | A Safety & Effectiveness Study of Intravenous Anidulafungin With AmBisome® for Treatment of Invasive Aspergillosis (IA). | Completed | Vicuron Pharmaceuticals | Phase 2/Phase 3 | 2002-05-01 | The combination of Anidulafungin plus AmBisome® may offer an improved outcome for patients treated for Invasive Aspergillosis (IA). The purpose of this study is to determine the safety and the clinical and microbiological effectiveness of anidulafungin plus AmBisome® in treated patients located in the United States, Europe, and South Africa. |
| NCT00037206 ↗ | A Safety & Effectiveness Study of Intravenous Anidulafungin With AmBisome® for Treatment of Invasive Aspergillosis (IA). | Completed | Pfizer | Phase 2/Phase 3 | 2002-05-01 | The combination of Anidulafungin plus AmBisome® may offer an improved outcome for patients treated for Invasive Aspergillosis (IA). The purpose of this study is to determine the safety and the clinical and microbiological effectiveness of anidulafungin plus AmBisome® in treated patients located in the United States, Europe, and South Africa. |
| NCT00037219 ↗ | The Safety and Effectiveness of Intravenous Anidulafungin as a Treatment for Patients With Invasive Candidiasis. | Completed | Vicuron Pharmaceuticals | Phase 2 | 2001-08-01 | Anidulafungin may be effective for the treatment of invasive Candida infections. The purpose of the study is to find the balance between dose tolerance and effectiveness of several doses for the treatment of United States patients with invasive candidiasis. |
| NCT00037219 ↗ | The Safety and Effectiveness of Intravenous Anidulafungin as a Treatment for Patients With Invasive Candidiasis. | Completed | Pfizer | Phase 2 | 2001-08-01 | Anidulafungin may be effective for the treatment of invasive Candida infections. The purpose of the study is to find the balance between dose tolerance and effectiveness of several doses for the treatment of United States patients with invasive candidiasis. |
| NCT00041704 ↗ | The Safety and Efficacy of Intravenous Anidulafungin as a Treatment for Azole-Refractory Mucosal Candidiasis (FRMC) | Completed | Vicuron Pharmaceuticals | Phase 2 | 2002-08-01 | Anidulafungin is an antifungal agent of the echinocandin class which is highly active in vitro against fluconazole resistant Candida species. The efficacy of anidulafungin has demonstrated in various animal models of fluconazole-resistant mucosal disease; as well as, in Phase 2 Esophageal Candidiasis studies. This study is intended to offer patients with FRMC an alternate therapy with amphotericin B or with other agents whose efficacy and/or safety are inadequate in the treatment of this disease. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Anidulafungin
Condition Name
Clinical Trial Locations for Anidulafungin
Trials by Country
Clinical Trial Progress for Anidulafungin
Clinical Trial Phase
Clinical Trial Sponsors for Anidulafungin
Sponsor Name
